FindTrial
Sign In

Effect of Empirical Administration of Cryoprecipitate with MHP on Trauma Patients with Hemorrhagic Shock

An Open-Label Parallel-Arm Randomized Controlled Trial on the Effectiveness of Prompt and Empirical Administration of Cryoprecipitate in Trauma Patients with Significant Hemorrhagic Shock - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/11/076324
Enrollment
80
Registered
2024-11-06
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R99- Ill-defined and unknown cause of mortality

Interventions

Intervention1: cryprecipitate: All the patients diagnosed as bleeding actively presenting in the Department of trauma surgery, JPNATC, New Delhi from May 2024 to April 2026 will be studied. The normal

Sponsors

AIIMS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Injured patients arriving within 6 hours of injury with provisional diagnosis of severe hemorrhagic shock requiring resuscitation with massive blood transfusion.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
To study the effect of early empirical administration of cryoprecipitate on the coagulation profile of a trauma patient with severe haemorrhagic shock, requiring massive blood transfusion.Timepoint: On arrival, at 12 hours and at 24 hours—

Secondary

MeasureTime frame
To study the effect of early empirical administration of cryoprecipitate on the survival of a trauma patient with severe haemorrhagic shock, requiring massive blood transfusion.Timepoint: on arrival & at discharge—

Countries

India

Contacts

Public ContactShakti Prakash Burman

AIIMS, New Delhi

narendra3483@gmail.com9911850813

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026